Cargando…
Weaning from intravenous prostanoids and normalization of hemodynamics by long-term imatinib therapy in severe idiopathic pulmonary arterial hypertension
Introduction Despite new treatment options targeted at its three main pathogenic pathways, prognosis of idiopathic pulmonary arterial hypertension has remained dismal, with 3-year survival rates around 70 %. Antiproliferative agents have emerged as a new therapeutic concept. However, they may exert...
Autores principales: | Speich, Rudolf, Treder, Ursula, Domenighetti, Guido, Huber, Lars C., Ulrich, Silvia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3984669/ https://www.ncbi.nlm.nih.gov/pubmed/24287663 http://dx.doi.org/10.1007/s11096-013-9881-x |
Ejemplares similares
-
Bone Mineral Density and Secondary Hyperparathyroidism in Pulmonary Hypertension
por: Ulrich, Silvia, et al.
Publicado: (2009) -
The German adaptation of the Cambridge pulmonary hypertension outcome review (CAMPHOR)
por: Cima, Katharina, et al.
Publicado: (2012) -
Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls: a cross sectional study
por: Ulrich, Silvia, et al.
Publicado: (2008) -
Caveolin-1 Expression and Hemodynamics in COPD Patients
por: Huber, Lars C, et al.
Publicado: (2009) -
Prostanoid therapies in the management of pulmonary arterial hypertension
por: LeVarge, Barbara L
Publicado: (2015)